Glenmark, Cipla plan to step up US manufacturing

Drugmakers Cipla Limited and Glenmark Pharmaceuticals are open to expanding their manufacturing footprint in the US - a move that could help shield them from potential disruptions linked to evolving tariff regime.

- ANJALI SINGH & SOHINI DAS

The US accounts for around a quarter of total revenue for both Cipla and Glenmark.

Cipla is "actively scaling operations in the US", a key global market for generics, particularly in respiratory and oncology segments, said a person familiar with the development. The company currently operates four manufacturing facilities in New York (3) and Massachusetts (1), focusing on inhalation products, oral therapy sachets, and the production of tablets and capsules. Cipla believes complex generics and peptide-based drugs are two areas where it can achieve longterm strategic growth.

Meanwhile, Glenmark is hopeful that its injectables facility in Monroe, North Carolina, will be back on track in FY26.

The company is open to expanding the site further. The facility, which had faced scrutiny from the US Food and Drug Administration (FDA), received a warning letter in 2023.